|
N
|
5-Year DDFS (%) (95 % CI)
|
HR (95 % CI)
|
p-valuea
|
---|
Age
|
< 35
|
30
|
82.6 [68.2–100]
|
1
| |
≥ 35
|
726
|
93.3 [91.2–95.4]
|
0.5 [0.2–1.3]
|
0.1223
|
SBR Grade
|
1–2
|
462
|
96 [94–98]
|
1
| |
3
|
285
|
87.4 [82.9–92.1]
|
2.8 [1.6–4.9]
|
0.0002
|
Pathological tumor size
|
pT1
|
391
|
93.6 [90.9–96.5]
|
1
| |
pT2
|
320
|
92.3 [88.9–95.7]
|
1.2 [0.7–2]
| |
pT3-T4
|
36
|
88.2 [78–99.8]
|
1.6 [0.6–4.7]
|
0.6395
|
PVI
|
No
|
558
|
94.2 [92–96.5]
|
1
| |
Yes
|
178
|
88.8 [83.5–94.5]
|
2.2 [1.3–4]
|
0.0042
|
Hormone receptors
|
Negative
|
208
|
88 [83–93.4]
|
1
| |
Positive
|
526
|
94.7 [92.5–96.9]
|
0.6 [0.3–1]
|
0.049
|
HER2
|
Negative
|
507
|
93.2 [90.5–95.9]
|
1
| |
Positive
|
96
|
95.7 [91–100]
|
0.9 [0.3–2.2]
|
0.7719
|
IHC subtypes
|
Luminal A
|
289
|
96.8 [94.5–99.2]
|
1
| |
Luminal B/HER2-negative
|
82
|
85.5 [76.3–95.8]
|
4.6 [1.8–11.7]
| |
Luminal B/HER2-positive
|
58
|
100 [100–100]
|
1.2 [0.2–5.5]
| |
HER2
|
37
|
89 [77.6–100]
|
2.9 [0.8–11.1]
| |
Triple-negative
|
127
|
89 [82.5–96]
|
3.3 [1.3–8.2]
|
0.0059
|
- HR hazard ratio, PVI peritumor vascular invasion
- aunadjusted log-rank test